期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

相关生物制剂在妊娠期和哺乳期风湿性疾病患者中的应用 被引量：3

Application of Biological Agents on Patients With Rheumatism During Pregnancy and Lactation
原文传递
导出
摘要 生物制剂是近年来在临床使用的一种基于基因工程的新型治疗药物。其中,依那西普、英夫利昔单抗、阿达木单抗及利妥昔单抗等,广泛应用于风湿性疾病的治疗,具有广阔的应用前景。目前,生物制剂对风湿性疾病的育龄妇女在妊娠期和哺乳期的影响,尚缺乏大样本量的双盲、随机对照试验。笔者拟就相关生物制剂在妊娠期和哺乳期风湿性疾病患者中的应用,综述如下。 Biological agents are a kind of new therapeutic drugs which based on genetic engineering for treating rheumatism in recent years, with a broad of application prospects in rheumatism. But the impact of biological agents on childbearing-age women during pregnancy and lactation, is still short of large sample size randomized controlled trials. This article focus on related literatures about the application of biological agents during pregnancy and lactation.
作者 刘艺 严冰 赵毅
机构地区 四川大学华西医院风湿免疫科
出处 《中华妇幼临床医学杂志（电子版）》 CAS 2013年第2期217-219,共3页 Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)
基金 国家自然科学基金面上项目(81273286)~~
关键词 生物制剂 妊娠 风湿性疾病 biological agents pregnancy rheumatism
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献15

  • 1Martin PL, Oneda S,Treacy G. Effects of an anti-TNF-alphamonoclonal antibody, administered throughout pregnancy andlactation,on the development of the macaque immune system[J],Am J Reprod Immunol, 2007, 58(2): 138-149.
  • 2Hazes JM,Coulie PG, Geenen V,et al. Rheumatoid arthritis andpregnancy: Evolution of disease activity and pathophysiologicalconsiderations for drug use[J], Rheumatology (Oxford),2011,50(11): 1955-1968.
  • 3Carter JD, Valeriano J , Vasey FB. Tumor necrosis factor-alphainhibition and VATER association: A causal relationship [J]. JRheumatol, 2006,33(5) ; 1014-101 7.
  • 4Crijns HJ, Jentink J, Garne E, n al. The distribution ofcongenital anomalies within the VACTERL association amongtumor necrosis factor antagonist-exposed pregnancies is similar tothe general population [J ]. J Rheumatol, 2011,38 ( 9 ): 1871-1874.
  • 5Carter JD, Ladhani A, Ricca LR, et al. A safety assessment oftumor necrosis factor antagonists during pregnancy: A review ofthe Food and Drug Administration database [J]. J Rheumatol,2009, 36(3): 635-641.
  • 6Van Assche G, Dignass A, Reinisch W, et al. The secondEuropean evidence-based Consensus on the diagnosis andmanagement of Crohn,s disease: Special situations[J]. J CrohnsColitis, 2010, 4(1) ; 63-101.
  • 7Vasiliauskas EA,Church JA, Silverman N,et al. Case report,Evidence for transplacental transfer of maternally administeredinfliximab to the newborn[J3. Clin Gastroenterol Hepatol, 2006,4(10): 1255-1258.
  • 8Ostensen M,Eigenmann GO. Etanercept in breast milk [ J ]. JRheumatol, 2004, 31(5): 1017-1018.
  • 9Mahmood I, Green MD. Drug interaction studies of therapeuticproteins or monoclonal antibodies[J]. J Clin Pharmacol, 2007,47(12): 1540-1554.
  • 10Ojeda-Uribe M, Afif N, Dahan E,et al. Exposure to abatacept orrituximab in the first trimester of pregnancy in three women withautoimmune disease.s[J]. Clin Rheumatol, 2013, 1-6.

同被引文献31

  • 1Flint J, Panchal S, Huh'ell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breasffeeding-Part II: anal- gesics and other drugs used in rheumatology practice [J]. Rheu- matology (Oxford),2016, pii: kev405. [ Epub ahead of print ].
  • 2Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: stan- dard and biologic disease modifying anti-rheumatic drugs and corticosteroids [J]. Rheumatology (Oxford),2016, 55 (9) : 1693- 1697.
  • 3Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammato- ry and immunosuppressive drugs and reproduction [J]. Arthritis Res Ther,2006,8(3):209.
  • 4Motta M, Ciardelli L, Marconi M, et al. Immune system develop- ment in infants born to mothers with autoimmune disease, ex- posed in utero to immunosuppressive agents [J ]. Am J Perinatol, 2007,24(8):441-447.
  • 5Gotestam SC, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnan- cy, and during pregnancy and lactation [J]. Ann Rheum Dis, 2016,75(5):795-810.
  • 6Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnan- cy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter co- hort study [ J ]. Arthritis Rheumatol,20i 4,66(5): 1101 - 1110.
  • 7Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohortstudy[J]. Rheumatology (Oxford),2014,53(4):757-763.
  • 8Levi S, Liberman M, Levi A J, et al. Reversible congenital neu- tropenia associated with maternal sulphasalazine therapy [J]. EurJ Pediatr,1988,148(2): 174-175.
  • 9Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy [J]. Arthritis Rheum,2010,62(5): 1494-1503.
  • 10Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumat- ic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers [J]. Scand J Rheumatol,2012,41 (3): 196-201.

引证文献3

二级引证文献8

中华妇幼临床医学杂志（电子版）
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部